Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 16/20 | 0.66 |
| ▸ | DRD2 | P14416 | 2/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | HTR7 | P34969 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.48 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1247196 | 0.90 | HTR6 (0.54) | HTR6DRD2HTR1AHTR7ADRB1 | |
| SCHEMBL1250029 | 0.90 | HTR6 (0.57) | HTR6DRD2HTR1AHTR7 | |
| SCHEMBL1250044 | 0.89 | HTR6 (0.53) | HTR6DRD2HTR1AHTR7HTR2C | |
| SCHEMBL1247186 | 0.88 | HTR6 (0.56) | HTR6DRD2HTR1AHTR7 | |
| SCHEMBL1250043 | 0.87 | HTR6 (0.54) | HTR6DRD2HTR1AHTR7HTR2C | |
| SCHEMBL1247204 | 0.87 | HTR6 (0.60) | HTR6DRD2HTR1AHTR7HTR2C | |
| SCHEMBL1249615 | 0.86 | HTR6 (0.54) | HTR6DRD2HTR1AHTR7 | |
| SCHEMBL1248579 | 0.86 | HTR6 (0.53) | HTR6DRD2HTR1AHTR7HTR2C | |
| SCHEMBL1248638 | 0.86 | HTR6 (0.49) | HTR6DRD2HTR1AHTR7HTR2C | |
| SCHEMBL1249595 | 0.86 | HTR6 (0.49) | HTR6DRD2HTR1AHTR7HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2285784-A1 | 1-(ARYLSULFONYL)-4-(PIPERAZIN-1-YL)-1H-BENZIMIDAZOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth LLC (US) | 2011-02-23 | — | — | EP | claimed |
| WO-2010056644-A1 | 1- (ARYLSULFONYL) -4- (PI PERAZIN-I -YL) -IH-BENZ IMIDAZOLES AS δ-HYDROXYTRYPTAMINE- 6 LIGANDS | WYETH LLC (US) | 2010-05-20 | — | — | WO | claimed |
| US-20100120779-A1 | 1-(ARYLSULFONYL)-4-(PIPERAZIN-1-YL)-1H-BENZIMIDAZOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2010-05-13 | — | — | US | claimed |
| US-8063053-B2 | 1-(arylsulfonyl)-4-(piperazin-1-yl)-1H-benzimidazoles as 5-hydroxytryptamine-6 ligands | WYETH LLC (US) | 2011-11-22 | — | — | US | disclosed |
| US-8063053-B2 | 1-(arylsulfonyl)-4-(piperazin-1-yl)-1H-benzimidazoles as 5-hydroxytryptamine-6 ligands | WYETH LLC (US) | 2011-11-22 | — | — | US | disclosed |
| US-8063053-B2 | 1-(arylsulfonyl)-4-(piperazin-1-yl)-1H-benzimidazoles as 5-hydroxytryptamine-6 ligands | WYETH LLC (US) | 2011-11-22 | — | — | US | disclosed |
| EP-2285784-A1 | 1-(ARYLSULFONYL)-4-(PIPERAZIN-1-YL)-1H-BENZIMIDAZOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth LLC (US) | 2011-02-23 | — | — | EP | disclosed |
| WO-2010056644-A1 | 1- (ARYLSULFONYL) -4- (PI PERAZIN-I -YL) -IH-BENZ IMIDAZOLES AS δ-HYDROXYTRYPTAMINE- 6 LIGANDS | WYETH LLC (US) | 2010-05-20 | — | — | WO | disclosed |
| US-20100120779-A1 | 1-(ARYLSULFONYL)-4-(PIPERAZIN-1-YL)-1H-BENZIMIDAZOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120779-A1 | 1-(ARYLSULFONYL)-4-(PIPERAZIN-1-YL)-1H-BENZIMIDAZOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120779-A1 | 1-(ARYLSULFONYL)-4-(PIPERAZIN-1-YL)-1H-BENZIMIDAZOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120779-A1 | 1-(ARYLSULFONYL)-4-(PIPERAZIN-1-YL)-1H-BENZIMIDAZOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | HTR6, TPH1, HTR4 | HTR6 1/4885DRD2 429/4885HTR1A 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.